

<!--StartFragment-->RESULT 2

AAD56890

ID AAD56890 standard; cDNA; 1279 BP.

XX

AC AAD56890;

XX

DT 06-NOV-2003 (first entry)

XX

DE Human diacylglycerol acyltransferase 2 (DGAT2) cDNA, 112023.

XX

KW Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;

KW coronary artery disease; hypertension; heart failure; tissue typing;

KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;

KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;

KW diabetes; chromosome mapping; forensic biology; enzyme; gene; ss.

XX

OS Homo sapiens.

XX

FH	Key	Location/Qualifiers
----	-----	---------------------

FT	CDS	42..1028
----	-----	----------

FT		/*tag= a
----	--	----------

FT		/product= "Human diacylglycerol acyltransferase 2"
----	--	--

XX

PN WO2003053363-A2.

XX

PD 03-JUL-2003.

XX

PF 19-DEC-2002; 2002WO-US040974.

XX

PR 19-DEC-2001; 2001US-0341947P.

PR 19-SEP-2002; 2002US-0411859P.

XX

PA (MILL-) MILLENNIUM PHARM INC.

XX

PI Gimeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;

XX

DR WPI; 2003-559092/52.

DR P-PSDB; AAE37790.

XX

PT New human diacylglycerol acyltransferase 2 (DGAT2) family member

PT polypeptide and nucleic acid molecules, useful for diagnosing and

PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or

PT triglyceride synthesis.

XX

PS Claim 1; Page 133-134; 154pp; English.

XX

CC The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)

CC family members and their uses. DGAT2 family member sequences or their

CC modulators are useful for diagnosing and treating a subject with a

CC disorder associated with the aberrant DGAT family member polypeptide

CC activity or nucleic acid expression, such as a disorder associated with

CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or

CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,

CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated

CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is

CC also useful in screening assays (e.g. tissue typing, chromosome mapping,

CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,

CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as

CC surrogate markers (e.g. markers of disease states or markers of drug

CC activity). The present sequence is human DGAT2 cDNA

XX

SQ Sequence 1279 BP; 273 A; 352 C; 328 G; 326 T; 0 U; 0 Other;

Query Match 95.9%; Score 1084.8; DB 2; Length 1279;
 Best Local Similarity 98.0%;
 Matches 1109; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

Qy	1	ACTGTTCTGAGATCTTTGCCTCCCTCAGGCTCCCGAGAATCATGGCTCATTCCAAGCAGC	60
Db	1	ACTGTTCTGAGATCTTTGCCTCCCTCAGGCTCCCGAGAATCATGGCTCATTCCAAGCAGC	60
Qy	61	CTAGTCACTTCCAGAGTCTGATGCTTCTGCAGTGGCCTTTGAGCTACCTTGCCATCTTTT	120
Db	61	CTAGTCACTTCCAGAGTCTGATGCTTCTGCAGTGGCCTTTGAGCTACCTTGCCATCTTTT	120
Qy	121	GGATCTTGCAGCCATTGTTTCGTCTACCTGCTGTTTACATCCTTGTGGCCGCTACCAGTGC	180
Db	121	GGATCTTGCAGCCATTGTTTCGTCTACCTGCTGTTTACATCCTTGTGGCCGCTACCAGTGC	180
Qy	181	TTTACTTTGCCTGGTTGTTTCCTGGACTGGAAGACCCAGAGCGAGGTGGCAGGCGTTCGG	240
Db	181	TTTACTTTGCCTGGTTGTTTCCTGGACTGGAAGACCCAGAGCGAGGTGGCAGGCGTTCGG	240
Qy	241	CCTGGGTAAGGAACTGGTGTGTCTGGACCCACATCAGGGACTATTTCCCCATTACGATCC	300
Db	241	CCTGGGTAAGGAACTGGTGTGTCTGGACCCACATCAGGGACTATTTCCCCATTACGATCC	300
Qy	301	TGAAGACAAAGGACCTATCACCTGAGCACAACCTACCTCATGGGGGTTACCCCCATGGCC	360
Db	301	TGAAGACAAAGGACCTATCACCTGAGCACAACCTACCTCATGGGGGTTACCCCCATGGCC	360
Qy	361	TCCTGACCTTTGGCGCCTTCTGCAACTTCTGCACTGAGGCCACAGGCTTCTCGAAGACCT	420
Db	361	TCCTGACCTTTGGCGCCTTCTGCAACTTCTGCACTGAGGCCACAGGCTTCTCGAAGACCT	420
Qy	421	TCCCAGGCATCACTCCTCACTTGGCCACGCTGTCCTGGTTCTTCAAGATCCCCTTTGTTA	480
Db	421	TCCCAGGCATCACTCCTCACTTGGCCACGCTGTCCTGGTTCTTCAAGATCCCCTTTGTTA	480
Qy	481	GGGAGTACCTCATGGCCAAAGGTGTGTGCTCTGTGAGCCAGCCAGCCATCAACTATCTGC	540
Db	481	GGGAGTACCTCATGGCCAAAGGTGTGTGCTCTGTGAGCCAGCCAGCCATCAACTATCTGC	540
Qy	541	TGAGCCATGGCACTGGCAACCTCGTGGGCATTGTAGTGGGAGGTGTGGGTGAGGCCCTGC	600
Db	541	TGAGCCATGGCACTGGCAACCTCGTGGGCATTGTAGTGGGAGGTGTGGGTGAGGCCCTGC	600
Qy	601	AAAGTGTGCCCAACACCACCACCTCATCTCCAGAAGCGCAAGGGGTTCTGTGCGCACAG	660
Db	601	AAAGTGTGCCCAAGACCACCACCTCATCTCCAGAAGCGCAAGGGGTTCTGTGCGCACAG	660
Qy	661	CCCTCCAGCATGGGGCTCATCTGGTCCCCACCTTCACTTTTGGGGAAACTGAGGTGTATG	720
Db	661	CCCTCCAGCATGGGGCTCATCTGGTCCCCACCTTCACTTTTGGGGAAACTGAGGTGTATG	720
Qy	721	ATCAGGTGCTGTTCCATAAGGATAGCAGGATGTACAAGTTCCAGAGCTGCTTCCGCCGTA	780
Db	721	ATCAGGTGCTGTTCCATAAGGATAGCAGGATGTACAAGTTCCAGAGCTGCTTCCGCCGTA	780
Qy	781	TCTTTGGTTTCTACTGTTGTGTCTTCTATGGACAAAGCTTCTGTCAAGGCTCCACTGGGC	840
Db	781	TCTTTGGTTTCTACTGTTGTGTCTTCTATGGACAAAGCTTCTGTCAAGGCTCCACTGGGC	840

```
Qy      841 TCCTGCCATACTCCAGGCCTATTGTCACTGTGGTTGGGGAGCCTCTGCCACTGCCCCAAA 900
        |||
Db      841 TCCTGCCATACTCCAGGCCTATTGTCACTGTGGTTGGGGAGCCTCTGCCACTGCCCCAAA 900

Qy      901 TTGAAAAGCCAAGCCAGGAGATGGTGGACAAATACCATGCACTTTATATGGATGCTCTGC 960
        |||
Db      901 TTGAAAAGCCAAGCCAGGAGATGGTGGACAAATACCATGCACTTTATATGGATGCTCTGG 960

Qy      961 ACAAACTGTTTCGACCAGCATAAGACCCACTATGGCTGCTCAGAGACCCAAAAGCTGTTTT 1020
        |||
Db      961 ACAAACTGTTTCGACCAGCATAAGACCCACTATGGCTGCTCAGAGACCCAAAAGCTGTTTT 1020

Qy      1021 TCCTGTGAATGAAGGTACTGTCATGCCCAGGAGCACAGGAGTGCCTGCC-TTGAAGAAGAG 1079
        |||
Db      1021 TCCTGTGAATGAAGGTACTGTCATGCCCAGGAGCACAGGAGTGCCTGCCTTTGAAGAAGAA 1080

Qy      1080 ACTCATCTGCCACTAACCAAAGACAGGCAGGAGATGAGGGAGGTTATATGTG 1131
        |||
Db      1081 GAATCATCTGGCATAACCAAAGACAGGCAGGAGATGAGGGAGGTTATATGTG 1132
<!--EndFragment-->
```